Document Type

Article

Publication Date

12-16-2024

Identifier

DOI: 10.3389/fphar.2024.1477485; PMCID: PMC11686437

Abstract

Flecainide acetate is a Class 1c anti-arrhythmic with a potent sodium voltage gated channel blockade which is utilized for the second-line treatment of tachyarrhythmias in children and adults. Given its narrow therapeutic index, the individualization of drug therapy is of utmost importance for clinicians. Despite efforts to improve anti-arrhythmic drug therapy, there remain knowledge gaps regarding the impact of variation in the genes relevant to flecainide's disposition and response. This variability is compounded in developing children whose drug disposition and response pathways may remain immature. The purpose of this comprehensive review is to outline flecainide's disposition and response pathways while simultaneously highlighting opportunities for prospective investigation in the pediatric population.

Journal Title

Front Pharmacol

Volume

15

First Page

1477485

Last Page

1477485

PubMed ID

39741635

Keywords

anti-arrhythmics; flecainide; ontogeny; pediatrics; pharmacogenomics; supraventricular tachycardia

Comments

Grants and funding

The authors declare that financial support was received for the research, authorship, and/or publication of this article. MW is supported by a Eunice Kennedy Shriver National Institute of Child Health and Human Development training grant (T32HD069038). This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Publisher's Link: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1477485/full

Download

Share

COinS